Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC

This study investigates whether patients with esophageal cancer (squamous cell type) who show a complete response — meaning scans and biopsies show no visible cancer — after immunotherapy plus chemotherapy and radiation can safely avoid surgery and be monitored closely instead. This approach is called 'watch and wait.' **You may be eligible if...** - You are 18–70 years old - You have been diagnosed with resectable (operable) esophageal squamous cell carcinoma - You are scheduled to receive combined chemotherapy and radiation (chemoradiotherapy) along with an immunotherapy drug called camrelizumab - Your cancer has not spread to other organs - Your heart, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have previously received chemotherapy, radiation, or surgery for esophageal cancer - You have an active autoimmune disease - You are taking long-term steroids or other immune-suppressing medications - You have uncontrolled infections or other serious illnesses Talk to your doctor to see if this trial is right for you.